Search Results

Stryker, a global leader in medical technologies, announced the launch of LIFEPAK 35 monitor/defibrillator, the latest product in the monitor/defibrillator space, offering advanced technology and built on an intuitive1, modern platform to help advance patient care.

Biond Biologics Ltd. today announced that the first patient has been dosed in a first-in-human clinical trial testing BND-35, a humanized ILT3/LILRB4 antagonist antibody.

Collegium Pharmaceutical, Inc. announced that it has entered into an Accelerated Share Repurchase agreement with Jefferies LLC to repurchase $35 million of the Company’s common stock.

Boehringer Ingelheim’s new program to cap out-of-pocket costs at $35 per month for eligible patientsi for the company’s inhalers is now available.

Elegen, the leader in next-generation DNA synthesis and production, announced a Series B financing of $35 million led by Triatomic Capital.

According to latest report, the U.S. Single-use Bioprocessing market size was USD 8.15 billion in 2023, calculated at USD 9.43 billion in 2024, and is expected to reach around USD 35.13 billion by 2033, expanding at a CAGR of 15.73% from 2024 to 2033.

BMS’ KarXT targets muscarinic receptors and “is at least 2-3 years ahead of the competition” including AbbVie and Neurocrine Biosciences, Truist Securities wrote in a note to investors.

According to latest report the global anti-inflammatory drugs market size was USD 120.46 billion in 2023, calculated at USD 130.70 billion in 2024, and is expected to reach around USD 272.35 billion by 2033, expanding at a CAGR of 8.5% from 2024 to 2033. North America anti-inflammatory drugs market accounted for over 41.11% market share in 2023.